Blue Jet Healthcare Ltd

- As of December, Blue Jet Healthcare Limited had Rs.410 crores in cash. - The company plans to use internal accruals initially for the Rs.1,000 crores CAPEX program planned over 3-4 years. - Management is open to both debt and equity financing options. - They have the ability to sell some shares to meet minimum promoter stake requirements (75%), indicating potential equity fundraising. - Co-investment options with customers are also being evaluated. - The company currently remains debt-free, providing flexibility to tap debt markets if needed. - No firm commitments made yet; options are being kept open to balance funding sources as the CAPEX progresses.

- **Vizag Greenfield Project**: Rs.1,000 crores approved CAPEX over the next 3-4 years to set up dedicated API and intermediates capacity aligned with customer demand; groundbreaking scheduled for February 2026; expected to strengthen global positioning. - **Unit 3 Expansion (Mahad)**: Nearing completion of core block for backward integration into contrast media intermediates; designed with automation and safety features; ready for qualification in Q1 FY27 to support growth and de-bottleneck supply chain. - **Hyderabad R&D Expansion**: New R&D center lease secured; development to start from Q3 FY27 focusing on emerging technologies like intermediates for GLP-1s, peptide chemistry, and bio-catalysis to support growing CDMO pipeline. - **Artificial Sweetener Pipeline**: Initiation of exhibit batches in FY27 to complement existing portfolio and address global demand. - **Funding Strategy**: Initial CAPEX funded via internal accruals and cash reserves (~Rs.410 crores as of Dec); options for debt, equity, or co-investment evaluated to maintain financial flexibility.

- The gadolinium-based NCE product is expected to reach a steady state with stable and sustainable yearly sales; modest growth possible in FY27 (Page 17). - Contrast media segment’s new launches and portfolio expansion aim to increase wallet share with large innovators, suggesting growth potential (Page 15). - FY27 expected to see commercial launch and ramp-up of new cardiovascular and NCE intermediate molecules contributing positively to revenue (Page 13). - Incremental pipeline includes new contrast media and API/PI products, indicating diversification and potential growth beyond current concentrations (Page 13). - Managing customer de-stocking and supply chain realignment might take a couple of quarters; growth recovery anticipated post-normalization (Pages 7, 16). - Co-investment options and long-term contracts are being explored to support growth and CAPEX deployment (Page 18).

- FY27 outlook is cautiously positive with expected commercial launch and ramp-up in key molecules starting Q1 FY27 (Page 13). - Management expects steady or modest growth rather than rapid spikes, with some new product launches anticipated but specifics awaited (Pages 10, 13). - Gross margins expected between 50%-55% depending on product mix; margins affected by operating leverage and product mix changes (Page 17). - PAT doubled from Rs.160 crores in 2024 to Rs.300 crores in 2025, indicating strong profitability growth history (Page 17). - Recent quarters affected by customer de-stocking and supply chain realignment; expected to normalize over a quarter or two leading to likely improved earnings (Pages 7, 17). - CAPEX of Rs.1,000 crores over next 3-4 years aimed at supporting growth; funding through internal accruals and flexible options without heavy leverage (Page 18). - Overall, earnings growth is expected to improve gradually as new capacities come online and destocking issues resolve.

- For the API, PI molecule, Blue Jet has binding forecasts and confirmed purchase orders for FY27, indicating a reasonably stable and sustainable order book. - Specific details on firm order quantities for FY27 are not disclosed, but management expresses confidence in the outlook without concern for dips. - The orders are partly subject to ongoing renegotiations, but historical momentum and multi-year supply agreements lend stability. - The company expects some lumpiness in pharma intermediates orders due to CDMO nature but aims for incremental year-on-year growth over the next five years. - For the new launches in contrast media, the company has capacity in place and discussions with customers for encouraging volumes in FY27 and beyond. - No exact quantitative order backlog figures were disclosed; instead, a positive outlook is maintained, with normalization expected over the next quarter or two.